MedTrace Logo

Anti-thrombotic and Glucose Lowering Therapy in Diabetic Patients Undergoing PCI

NCT04481997 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-08-29

No results posted yet for this study

Summary

Diabetes mellitus (DM) is one of the main risk factors for ischemic events in patients with coronary artery disease (CAD) and diabetes is a factor in several post-PCI (Percutaneous Coronary Intervention) risk scores. However, until recently, there were almost no studies performed specifically in the diabetic population of patients undergoing PCI. This study aims to describe the anti-thrombotic regimens, clinical outcomes and current diabetes medical treatment in an unselected consecutive population of patients with DM undergoing PCI.

Conditions

Interventions

OTHER

Exposure to Anti-thrombotic treatment agents and glucose lowering therapy

Exposure to Anti-thrombotic treatment agents and glucose lowering therapy

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Cardiovascular Centre of Universidade de Lisboa (CCUL)

    collaborator UNKNOWN

  • Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA

    lead OTHER

Principal Investigators

  • Sérgio B Baptista, PhD · Cardiovascular Centre of the University of Lisbon (CCUL)

  • Luís Raposo, MD · Hospital de Santa Cruz, CHLO, EPE, Lisbon, Portugal

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-11
Primary Completion
2023-11-04
Completion
2024-01-30

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04481997 on ClinicalTrials.gov